title: [Inhibitor of apoptosis in lung cancer Livin perioperative clinical research].
abstract: OBJECTIVE
  To detect the inhibitor of apoptosis protein Livin in non-small cell lung cancer patients with perioperative serum levels were analyzed trends in perioperative period to explore the Livin in non-small cell lung cancer diagnosis, classification and prognosis of clinical significance.
  
  
  METHODS
  Enzyme-linked immunosorbent assay (ELISA) of 40 patients with non-small cell lung cancer patients before surgery, the serum levels of Livin expression and 20 cases of normal healthy human serum levels of Livin were detected.
  
  
  RESULTS
  Non-small cell lung cancer patients was significantly higher than the level of serum Livin healthy control group. Before surgery (median 526.49 ng/L, quartile 357.93-825.57 ng/L), postoperative (median 286.49 ng/L, quartile 157.93-515.57 ng/L), there was significant difference between the two groups (P<0.05).Livin the average level of serum with non-small cell lung cancer the relationship between pathology: I, II period (median 326.49 ng/L, quartile 201.54-623.19 ng/L) and stage III (median 586.31 ng/L, quartile 411.79-965.34 ng/L) statistically significant difference between (P<0.05); tumor lymph node metastasis in 11 cases (median 562.03 ng/L, quartile 382.64-982.61 ng/L) and the 29 cases without lymph node metastasis (median 344.59 ng/L, quartile 167.27-646.20 ng/L) significant difference between (P<0.05); organization credits of: high, medium, poorly differentiated among the three groups without significant differences (P>0.05).
  
  
  CONCLUSIONS
  Livin as a new inhibitor of apoptosis protein in non-small cell lung cancer diagnosis, staging has some clinical value.
authors.affiliation: Division of Respiratory Diseases the Assiliated Hospital in Xi'an Medical College, Xi'an 710077, China.
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Wang
authors.forename: Jian
authors.initials: J
authors.lastname: Mou
authors.forename: Yan-Bing
authors.initials: YB
authors.lastname: Zhang
authors.forename: Ping
authors.initials: P
authors.lastname: Dong
authors.forename: Xin
authors.initials: X
authors.lastname: Diao
authors.forename: Sheng-Yu
authors.initials: SY
authors.lastname: Wang
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.forename: Yan-Feng
authors.initials: YF
authors.lastname: Liu
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000032:analysis / Q000097:blood*; D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000473:pathology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000032:analysis / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000473:pathology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000097:blood*; D009367:Neoplasm Staging; D059035:Perioperative Period / Q000379:methods; D011379:Prognosis
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C419866:BIRC7 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D009363:Neoplasm Proteins